Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : STEM -- StemCells, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: WWS who wrote (194)	1/25/1999 7:18:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 805

Geeeze, you guys are finding good stuff. >> Another caveat lies in whether the grafted cells will cause an immune response in the human host. Though previous rodent work suggests they will not, this question remains unanswered.<< I'll have to see it before I believe it. I still feel that this sort of therapy is likely to be at least more effective if the cells are autologous. So, you want to treat a 70 year old patient for Parkinson's? Can you harvest stem cells from such a patient, or are they exhausted? Is it safe? Would that be a rational target for clinical trials if effective therapy did require patient-specific transplantation? Wonder if these companies (GERN, CTII, etc.) are beginning to talk to BioTransplant regarding the induction of tolerance?

To: WWS who wrote (194)	1/28/1999 8:05:00 AM
From: Jim Oravetz	Read Replies (1) \| Respond to of 805

usnews.com A stem-cell go-ahead National Institutes of Health give an OK to controversial research after legal review ...Well aware that it's walking a political tightrope, the agency plans to set up stringent oversight committees that go above and beyond its traditional peer review process. Despite the months-long wait before the money flows, biologists are delighted. "It'll be a breath of fresh air," says James Robl, a reproductive and developmental biologist at the University of Massachusetts–Amherst. "The time frame from stem cells to therapeutic use is going to be reduced significantly." Sorry if this has been posted already. This is out of the latest issue of US News & World report. Jim